Drug Profile
OMTX 503
Alternative Names: MTX3-NIG; OMTX-503Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Oncomatryx
- Class Antineoplastics; Immunoconjugates
- Mechanism of Action Ribosome inactivating protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ewing's sarcoma; Pancreatic cancer
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Ewing's Sarcoma in Spain (unspecified route) (Oncomatryx pipeline, September 2023)
- 12 Sep 2023 Discontinued - Preclinical for Pancreatic cancer in Spain (unspecified route) (Oncomatryx pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Ewing's Sarcoma in Spain